194 related articles for article (PubMed ID: 27756370)
1. An analysis of common ethical justifications for compassionate use programs for experimental drugs.
Raus K
BMC Med Ethics; 2016 Oct; 17(1):60. PubMed ID: 27756370
[TBL] [Abstract][Full Text] [Related]
2. Ethical justifications for access to unapproved medical interventions: an argument for (limited) patient obligations.
Walker MJ; Rogers WA; Entwistle V
Am J Bioeth; 2014; 14(11):3-15. PubMed ID: 25325801
[TBL] [Abstract][Full Text] [Related]
3. Right-to-Try Investigational Therapies for Incurable Disorders.
Simmons Z
Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. PubMed ID: 28968371
[TBL] [Abstract][Full Text] [Related]
4. Dilemmas in the compassionate supply of investigational cancer drugs.
Lewis JR; Lipworth W; Kerridge I; Doran E
Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
[TBL] [Abstract][Full Text] [Related]
5. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
Hordijk M; Vermeulen SF; Bunnik EM
Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
[TBL] [Abstract][Full Text] [Related]
6. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
Buckley M; O'neil C
J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
[TBL] [Abstract][Full Text] [Related]
7. From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs.
Sandman L; Liliemark J
Semin Cancer Biol; 2017 Aug; 45():58-63. PubMed ID: 28578075
[TBL] [Abstract][Full Text] [Related]
8. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
9. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
Bunnik EM; Aarts N; van de Vathorst S
Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
[TBL] [Abstract][Full Text] [Related]
10. Access to experimental medicines for TB: ethical and human rights considerations.
Dagron S; Chakhaia T; González-Angulo L; Hermanns S; Skrahina A; Wallace AEM
Int J Tuberc Lung Dis; 2020 May; 24(5):38-43. PubMed ID: 32553042
[TBL] [Abstract][Full Text] [Related]
11. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
Bunnik EM; Aarts N
BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
[TBL] [Abstract][Full Text] [Related]
12. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
[TBL] [Abstract][Full Text] [Related]
13. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
Schüklenk U; Lowry C
Br Med Bull; 2009; 89():7-22. PubMed ID: 19056723
[TBL] [Abstract][Full Text] [Related]
14. Compassionate use programs in Italy: ethical guidelines.
De Panfilis L; Satolli R; Costantini M
BMC Med Ethics; 2018 Mar; 19(1):22. PubMed ID: 29523198
[TBL] [Abstract][Full Text] [Related]
15. Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.
Mackey TK; Schoenfeld VJ
BMC Med; 2016 Feb; 14():17. PubMed ID: 26843367
[TBL] [Abstract][Full Text] [Related]
16. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
17. The ethical plausibility of the 'Right To Try' laws.
Carrieri D; Peccatori FA; Boniolo G
Crit Rev Oncol Hematol; 2018 Feb; 122():64-71. PubMed ID: 29458791
[TBL] [Abstract][Full Text] [Related]
18. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Jecker NS
Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
[No Abstract] [Full Text] [Related]
19. Compassionate use of gene therapies in pediatrics: An ethical analysis.
Neuhaus CP; Zacharias RL
Semin Perinatol; 2018 Dec; 42(8):508-514. PubMed ID: 30389228
[TBL] [Abstract][Full Text] [Related]
20. Characterizing expanded access and compassionate use programs for experimental drugs.
Miller JE; Ross JS; Moch KI; Caplan AL
BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
